In a post-mortem analysis of the REDEFINE 1 trial announced at Obesity Week 2026, Novo Nordisk's Cagrisema achieved an average weight loss of 25% among early responders.

Zhitongcaijing · 1d ago
In a post-mortem analysis of the REDEFINE 1 trial announced at Obesity Week 2026, Novo Nordisk's Cagrisema achieved an average weight loss of 25% among early responders.